FY2029 Earnings Estimate for DMAC Issued By HC Wainwright

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Research analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of DiaMedica Therapeutics in a research note issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now forecasts that the company will earn $0.08 per share for the year, up from their prior forecast of $0.06. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.18). During the same period in the prior year, the business earned ($0.14) earnings per share.

DiaMedica Therapeutics Stock Up 3.2%

Shares of NASDAQ DMAC opened at $4.20 on Friday. The firm has a market capitalization of $180.00 million, a P/E ratio of -7.50 and a beta of 1.29. The stock’s 50-day simple moving average is $4.13 and its two-hundred day simple moving average is $4.99. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $6.82.

Hedge Funds Weigh In On DiaMedica Therapeutics

Several institutional investors have recently modified their holdings of DMAC. Bank of Montreal Can purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at about $84,000. Raymond James Financial Inc. purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at about $83,000. Y Intercept Hong Kong Ltd purchased a new stake in DiaMedica Therapeutics during the 4th quarter valued at about $81,000. LPL Financial LLC lifted its holdings in DiaMedica Therapeutics by 8.2% in the 4th quarter. LPL Financial LLC now owns 152,000 shares of the company’s stock worth $825,000 after buying an additional 11,500 shares during the period. Finally, Susquehanna International Group LLP lifted its holdings in DiaMedica Therapeutics by 269.5% in the 4th quarter. Susquehanna International Group LLP now owns 374,845 shares of the company’s stock worth $2,035,000 after buying an additional 273,395 shares during the period. 10.12% of the stock is currently owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.